Higher serum total bilirubin levels associated with lower long-term risk in coronary heart disease patients
High bilirubin levels linked to lower heart risk in some cases
This meta-analysis examined the association between serum total bilirubin and major adverse cardiovascular events in patients undergoing per…
New data suggests high bilirubin might protect patients with coronary heart disease from long-term risks, though the evidence is still early…
Supraventricular tachyarrhythmias occur more frequently in patients with Arrhythmogenic Cardiomyopathy and Brugada Syndrome
Heart conditions like Brugada syndrome increase risk of rapid heartbeats
This systematic review of 30 studies indicates that supraventricular tachyarrhythmias (SVT) are more frequent in patients with Arrhythmogeni…
Patients with certain heart conditions face a higher risk of fast heartbeats, which can lead to complications like heart failure or unnecess…
Higher Triglyceride-glucose index levels are associated with increased risk of Atrial Fibrillation
Higher Triglyceride-Glucose Index Linked to Increased Risk of Atrial Fibrillation
This meta-analysis of 25,376 individuals found significantly higher TyG index levels in patients with Atrial Fibrillation compared to those …
A high triglyceride-glucose index may serve as a potential marker for identifying people at risk for atrial fibrillation and related heart c…
Gut microbiota-derived aromatic amino acid metabolites influence myocardial injury and risk of major adverse cardiac events
Gut Microbiota Metabolites Linked to Cardiovascular Disease Risk
This systematic review synthesizes the roles of gut microbiota-derived aromatic amino acid (AAA) metabolites in cardiovascular disease. The …
Specific compounds from gut bacteria, like Phenylacetylglutamine, are linked to heart damage and increased risks for cardiovascular disease.
FDA Approves Furoscix (furosemide) for Edema in Heart Failure and CKD
FDA approves new diuretic Furoscix for heart and kidney patients
The FDA approved Furoscix (furosemide) subcutaneous injection for edema in pediatric patients weighing 43 kg and above and in adults with ch…
The FDA approved Furoscix (furosemide) to treat fluid buildup in adults and children weighing 43 kg or more with chronic heart failure or ki…
FDA Approves Ziac (bisoprolol/hydrochlorothiazide) for Hypertension
FDA approves Ziac, a new combination pill for high blood pressure.
FDA approved Ziac (bisoprolol fumarate/hydrochlorothiazide) for the management of hypertension. The combination provides additive blood pres…
The FDA approved Ziac, a combination of two blood pressure medicines, for treating hypertension. It is for patients who need more than one d…
FDA Approves Avapro (irbesartan) for Hypertension and Diabetic Nephropathy
FDA approves Avapro to treat high blood pressure and kidney disease in diabetes.
FDA approved Avapro (irbesartan) for hypertension and for diabetic nephropathy in hypertensive type 2 diabetes patients with elevated creati…
The FDA approved Avapro (irbesartan) for high blood pressure and for kidney disease in people with type 2 diabetes. It helps lower blood pre…
Behavioral and metabolic factors characterize a distinct premature atherosclerosis phenotype in Chinese patients
Smoking and Metabolic Factors Linked to Heart Attacks in China
This systematic review of 317 observational studies maps risk factors for premature myocardial infarction (PMI) in China. The synthesis iden…
A large review of 317 studies identifies specific behavioral and metabolic risk factors for heart attacks among Chinese patients.
Novel pharmacotherapies like resmetirom and GLP-1 receptor agonists offer potential concurrent hepatic and cardiovascular benefits
New Medications Show Potential to Treat Liver and Heart Disease
This systematic review examines the epidemiological links and shared pathophysiological mechanisms between metabolic dysfunction-associated …
Newer drugs like resmetirom and GLP-1 receptor agonists may offer dual benefits for patients with both liver and heart conditions.
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients
Ticagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients
This meta-analysis of 31,729 adult STEMI patients post-PCI found that ticagrelor significantly reduced all-cause mortality (OR = 0.64) and m…
A large analysis of over 31,000 patients suggests ticagrelor may lower mortality and heart attack risks compared to clopidogrel after a hear…
Antazoline May Beat Propafenone and Amiodarone for AF Conversion
Antazoline shows better results for atrial fibrillation heart rhythms
A meta-analysis suggests antazoline is more effective than propafenone or amiodarone for converting atrial fibrillation to sinus rhythm, wit…
A new review suggests antazoline may be more effective than common medications at restoring normal heart rhythms for patients with atrial fi…
Ferroptosis regulation via phytochemicals and targeted delivery systems offers potential to mitigate doxorubicin-induced cardiotoxicity
New strategies may protect heart during chemo without reducing cancer fight
This systematic review examines the mechanisms of myocardial ferroptosis during doxorubicin treatment and evaluates various intervention str…
A review reveals innovative ways to shield the heart from doxorubicin damage while keeping its cancer-killing power intact.